Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Lymphoid 1Gastrointestinal 1Dermatologic 1

Conditions

Sarcoma, Kaposi 1Recurrence 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1HIV Infections 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 6Magnetic Resonance Spectroscopy 6Specimen Handling 5Cyclophosphamide 5Radiosurgery 3Oncolytic Virotherapy 3Nivolumab 3Injections 3Gemcitabine 3Drug Therapy 3Biopsy 3fludarabine 2belinostat 2Riluzole 2Paclitaxel 2Ipilimumab 2Filgrastim 2Docetaxel 2Cisplatin 2Celecoxib 2Carboplatin 2Bortezomib 2Blood Specimen Collection 2Amifostine 2AH 111585 2tislelizumab 1spartalizumab 1seribantumab 1selpercatinib 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × Antiretroviral Therapy, Highly Active × Sarcoma × Clear all
NCT02595866 2024-08-09

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

National Cancer Institute (NCI)

Phase 1 Completed
58 enrolled 17 charts
DermatologicGastrointestinalLymphoidSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence, Sarcoma, Kaposi, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡